Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Comparative pharmacokinetics and biodistribution of HAEE and HASS peptides

Ivanova AV, Lazareva PA, Kuzmichev IA, Vadekhina VV, Kosykh AV, Gurskaya NG, Abakumov MA
About authors

Research Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia

Correspondence should be addressed: Anna V. Ivanova
Ostrovityanova, 1, str. 1, Moscow, 117513, Russia; ur.xednay@tirofsof.repus

About paper

Funding: the study was conducted under the State Assignment “Development of a Radiopharmaceutical for the Diagnosis of Alzheimer's disease Using the HAEE Tetrapeptide as a Vector Molecule”, EGISU R&D registration number 1024110600012-8-3.2.25;3.2.26;3.2.12.

Author contribution: Ivanova AV — literature review, BALB/с mouse model experimental research, ensuring transcardiac perfusion of all organs, manuscript writing; Lazareva PA — BALB/с mouse model experimental research, ensuring transcardiac perfusion of all organs, analysis of the results, manuscript writing; Kuzmichev IA — synthesis of HAEEGGGGK-Cy5 and HASSGGGGGK-Cy5 fluorescent peptides; Vadekhina VV — intravenous tail vein injection of HAEEGGGGK-Cy5 and HASSGGGGGK-Cy5 peptides, ensuring transcardiac perfusion of all organs; Kosykh AV — fixation, histology slide preparation for microscopic imaging, imaging and manuscript writing; Gurskaya NG — imaging using the fluorescence microscope and analysis, manuscript writing; Abakumov MA — goal setting, developing the study design, manuscript writing; all the authors contributed to preparation of the paper equally, they confirmed compliance of their authorship with the international ICMJE criteria.

Compliance with ethical standards: the study approved by the Ethics Committee of the Pirogov Russian National Research Medical University (protocol 03/2025 dated 23 January 2025) was conducted in accordance with the principles of Good Laboratory Practice (Order of the Ministry of Health of the Russian Federation No. 708n dated 23.08.2010, Directive 2010/63/EU of the European Parliament and of the Council on the protection of animals used for scientific purposes).

Received: 2025-07-10 Accepted: 2025-07-24 Published online: 2025-07-31
|
  1. Huang LK, Kuo HY, Chen HJ, et al. Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update. J Dent Res. 2023; 88 (3): 1–19.
  2. Facts D. Alzheimer's disease facts and figures report: executive summary. Alzheimers Dement. 2024; 20 (5): 40–42.
  3. Adlard PA, Bush AI. A review of β-amyloid neuroimaging in Alzheimer's disease. Front Neurosci. 2014; 8 (OCT): 1–23.
  4. Thies W, Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement. 2011; 7 (2): 208–44.
  5. Tackenberg C, Kulic L, Nitsch RM. Familial Alzheimer's disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system. PLoS One. 2020; 15 (9): 1–14.
  6. Hayne DJ, Lim S, Donnelly PS. Metal complexes designed to bind to amyloid-β for the diagnosis and treatment of Alzheimer's disease. Chem Soc Rev. 2014; 43 (19): 6701–15.
  7. Carroll CM, Li YM. Physiological and pathological roles of the γ-secretase complex. Brain Res Bull. 2016; 126: 199–206.
  8. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol. 2007; 8 (2): 101–12.
  9. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010; 9 (5): 387–98.
  10. Masters CL, Simms G, Weinman NA, et al. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem. 2006; 97 (6): 1700–25.
  11. Masters CL, Beyreuther K. Science, medicine, and the future: Alzheimer's disease. BMJ. 1998; 316 (7129): 446.
  12. Hippius H, Neundörfer G. The discovery of Alzheimer's disease. Dialogues Clin Neurosci. 2003; 5 (1): 101–8.
  13. Zolotarev YA, Dadayan AK, Bocharov EV, et al. Pharmacokinetics and molecular modeling indicate nAChRα4-derived peptide HAEE goes through the blood-brain barrier. Biomolecules. 2021; 11 (6): 902.
  14. Maack T, Johnson V, Kau ST, et al. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 1979; 16 (3): 251–70.
  15. Agu RU, Ugwoke MI, Armand M, et al. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res. 2001; 2 (4): 198–209.